Related Experiment Video
Updated: Jun 4, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis
K R Herrlinger1, H Koc, S Winter
1Department of Gastroenterology, Hepatology and Endocrinology, Robert-Bosch-Hospital, Stuttgart, Germany. klaus.herrlinger@rbk.de
Clinical Pharmacology and Therapeutics
|February 4, 2011
Summary
Genetic variants in ABCB1 may predict short-term remission in patients with ulcerative colitis (UC) treated with tacrolimus (Tac). This finding could help personalize tacrolimus therapy for UC, improving treatment outcomes and reducing side effects.
Area of Science:
- Pharmacogenomics
- Gastroenterology
- Internal Medicine
Background:
- Tacrolimus (Tac) is effective for steroid-refractory ulcerative colitis (UC), but nonresponse and side effects limit its use.
- Tac response in transplant patients is linked to CYP3A and ABCB1 gene variants.
- Understanding genetic predictors of Tac response in UC is crucial for optimizing treatment.
Purpose of the Study:
- To investigate the association between specific genetic polymorphisms in CYP3A4, CYP3A5, and ABCB1 and Tac response in patients with UC.
- To determine if these polymorphisms can predict short-term remission and colectomy-free survival in UC patients treated with Tac.
Main Methods:
- Genotyping of CYP3A4*1B, CYP3A5*3, and ABCB1 (1236C>T, 2677G>T/A, 3435C>T) polymorphisms in 89 UC patients.
- Assessment of short-term remission, response, and colectomy-free survival.
- Statistical analysis using linear logistic regression and multivariate analysis, with correction for dose-adjusted Tac blood trough levels.
Main Results:
- Short-term remission and response were achieved in 61% and 14% of patients, respectively.
- Patients with homozygous variants in any of the three ABCB1 alleles demonstrated significantly higher short-term remission rates.
- The predictive effect of ABCB1 variants remained significant after multivariate analysis and correction for Tac blood levels.
Conclusions:
- ABCB1 gene polymorphisms, but not CYP3A5*3, may serve as a predictor of short-term remission in patients with steroid-refractory UC treated with Tacrolimus.
- These findings suggest a potential role for pharmacogenetic testing to personalize Tacrolimus therapy in UC.
- Further research is warranted to validate these genetic markers in larger cohorts.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...